YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: A multi-center study

Brazilian Journal of Infectious Diseases

Volumn 16, Issue 3, 2012, Pages 250-255

  Tan, You Wen ^a   Ge, Guo Hong ^a   Zhao, Wei ^b   Gan, Jian He ^c   Zhao, Yun ^d   Niu, Zhi Lin ^e   Zhang, Dong Jun ^e   Chen, Li ^a   Yu, Xue Jun ^a   Yang, Li Jun ^a  

^a The No 3 People's Hospital of Zhenjiang   (China)

^b The No 2 Hospital of Nanjin   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d YANGZHOU UNIVERSITY   (China)

^e NANTONG MEDICAL COLLEGE   (China)

Author keywords

Anti viral therapy; Chronic hepatitis B; Mutations; YMDD

Indexed keywords

ANTIVIRUS AGENT; ASPARTIC ACID; FAMCICLOVIR; HEPATITIS B(E) ANTIGEN; ISOLEUCINE; LAMIVUDINE; LEUCINE; METHIONINE; NUCLEIC ACID; PROTEIN VARIANT; TYROSINE; VALINE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HOSPITAL PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OUTPATIENT DEPARTMENT; PROTEIN MOTIF; REAL TIME POLYMERASE CHAIN REACTION; WILD TYPE;

ADULT; AMINO ACID MOTIFS; ANTIVIRAL AGENTS; ASPARTIC ACID; DNA, VIRAL; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; METHIONINE; MUTATION; POLYMERASE CHAIN REACTION; TYROSINE;

EID: 84862016665     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/S1413-8670(12)70319-7     Document Type: Article

References (28)

1. de Franchis R., Hadengue A., Lau G., et al. EASL International Consensus Conference on Hepatitis B. 13-14 September 2002, Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003, 39(Suppl. 1):S3-S25.
2. Tipples G.A., Ma M.M., Fischer K.P., Bain V.G., Kneteman N.M., Tyrrell D.L. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996, 24:714-717.
3. Allen M.I., Deslauriers M., Andrews C.W., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27:1670-1677.
4. Honkoop P., Niesters H.G., de Man R.A., Osterhaus A.D., Schalm S.W. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J. Hepatol 1997, 26:1393-1395.
5. Niesters H.G., Honkoop P., Haagsma E.B., de Man R.A., Schalm S.W., Osterhaus A.D. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998, 177:1382-1385.
6. Kobayashi S., Ide T., Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J. Hepatol 2001, 34:584-586.
7. Kirishima T., Okanoue T., Daimon Y., et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 2002, 37:259-265.
8. Heo J., Cho M., Kim H.H., et al. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J Korean Med Sci 2004, 19:541-546.
9. Akarsu M., Sengonul A., Tankurt E., et al. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J Hepatology 2006, 21:1783-1788.
10. Matsuda M., Suzuki F., Suzuki Y., et al. Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine. J Gastroenterol 2004, 39:34-40.
11. Matsuda M., Suzuki F., Suzuki Y., et al. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine. J Med Virol. 2004, 74:361-366.
12. Huang Z.M., Huang Q.W., Qin Y.Q., et al. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol 2005, 11:867-870.
13. Min X.C., Miao X.H., Zhao S.M., Zhao K.K., Yang D.G. The spontaneous YMDD mutation rate in chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 2009, 17(12):887-890.
14. Stuyver L., Van Geyt C., De Gendt S., et al. Line probe assay for monitoring drug resistance in hepatitis B virusinfected patients during antiviral therapy. J Clin Microbiol 2000, 38:702-707.
15. Aberle S.W., Kletzmayr J., Watschinger B., Schmied B., Vetter N., Puchhammer-Stöckl E. Comparison of sequence analysis and the INO-LIPA HBV DR line probe assay for detection of lamivudineresistant hepatitis B virus strains in patients under various clinical conditions. J Clin Microbiol 2001, 39:1972-1974.
16. Pas S.D., de Man R.A., Fries E., Osterhaus A.D., Niesters H.G. The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation. J Clin Virol 2002, 25:63-71.
17. Niesters H.G., Zoulim F., Pichoud C., et al. Validation of the INO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment. Antimicrob Agents Chemother 2010, 54:1283-1289.
18. The guidelines of prevention and treatment for chronic hepatitis B. Chin Hepatol Dis J 2011, 19:13-23. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.
19. Kobayashi S. Clinical characteristics of asymptomatic hepatitis B virus carriers with YMDD mutant not treated with lamivudine. Kurume Med J 2003, 50:87-90.
20. Da Silva L.C., da Fonseca L.E., Carrilho F.J., Alves V.A., Sitnik R., Pinho J.R. Predictive factors for response to lamivudine in chronic hepatitis B. Rev Inst Med Trop São Paulo 2000, 42:189-196.
21. Ye X.G., Wang R.L., Guo H.B. Detection and analysis of YMDD mutate genes in patients of chronic hepatitis B before being treated. Zhonghua Jianyan Yixue Zazhi 2002, 25:248.
22. Tassopoulos N.C., Volpes R., Pastore G., et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine precore mutant study group. Hepatology 1999, 29:889-896.
23. Yuen M.F., Tanaka Y., Lai C.L. Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy. Intervirology 2003, 46:373-376.
24. Sánchez-Tapias J.M., Costa J., Mas A., Bruguera M., Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002, 123:1848-1856.
25. Rodriguez-Novoa S., Gomez-Tato A., Aguilera-Guirao A., et al. Hepatitis B virus genotyping based on cluster analysis of the region involved in lamivudine resistance. J Virol Methods 2004, 115:9-17.
26. Zhou D.Y., Lin L.Y., Wang H., Huang J.S. The relationship between HBV lamivudine resistance and HBV genotypes or basic core promoter mutations. Hepatobiliary Pancreat Dis Int 2003, 2:85-89.
27. Yano M., Ohkoshi S., Suzuki K., et al. Absence of pretreatment markers that predict the emergence of YMDD mutants during lamivudine treatment - the results of a prospective multi-center study. Hepatogastroenterology 2006, 53(67):124-127.
28. Shi M., Yang Z.J., Wang R.S., et al. Rapid quantitation of lamivudine-resistant mutants in lamivudine treated and untreated patients with chronic hepatitis B virus infection. Clin Chim Acta 2006, 373(1-2):172-175.